Article | July 11, 2022

How Will COVID-Era Clinical Trials Changes Affect Future Research?

By David Blackman, Executive Director Digital Trials Strategy

Science technology concept Laboratory Examination Research iStock-1180547351

In new research based on a global survey by Informa Pharma Intelligence and Oracle, 84% of professionals involved in clinical trials at biopharmaceutical companies, medical device companies, and CROs reported using alternative approaches to continue existing trials or start new clinical trials during the pandemic.

The question is—will these changes remain, and if so, what does this mean for the future of clinical trials?

access the Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Oracle Life Sciences